VIDEO: Triplet therapy improved PFS in relapsed, refractory follicular lymphoma

ByPaolo Caimi MD

ByErin Michael

Fact checked byMindy Valcarcel, MS

SAN DIEGO — Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind trial presented at ASH Annual Meeting and Exposition.

The phase 3 study assessed the use of tafasitamab-cxix (Monjuvi; MorphoSys, Incyte) plus lenalidomide and rituximab (Rituxan; Genentech, Biogen) compared with placebo, lenalidomide and rituximab in patients with advanced follicular lymphoma.

Caimi explained that the findings showed that “1 year of the triplet combination seems to be better than the doublet in patients with relapsed follicular lymphoma.”

Reference:

Sehn LH, et al. Abstract LBA-1. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Caimi reports serving on the advisory board for ADC Therapeutics, Bristol Myers Squibb, Genentech, Luminary Therapeutics, Novartis and Synthekine; receiving honoraria from AbbVie, Arvinas, Recordati and Sobi; and research funding from AbbVie, Abcon, ADC Therapeutics, Arvinas, Bristol Myers Squibb, Genentech, Genmab, Luminary Therapeutics, Profound Bio, Recordati and Synthekine.

Take Homes in Lymphoma

Read more

VIDEO: Triplet therapy improved PFS in relapsed, refractory follicular lymphoma

Reference:

Related Content